【摘要】：作為七大戰(zhàn)略性新興產(chǎn)業(yè)之一，生物制藥產(chǎn)業(yè)的國(guó)民經(jīng)濟(jì)支柱性產(chǎn)業(yè)地位和國(guó)際戰(zhàn)略性新興產(chǎn)業(yè)地位日益凸顯。近年來(lái)一批生物制藥上市公司利用資本市場(chǎng)的有力支持，迅速崛起，不僅形成了備受矚目的生物制藥板塊，而且有力推動(dòng)了中國(guó)生物制藥產(chǎn)業(yè)的發(fā)展，未來(lái)生物制藥上市公司具有更加廣闊的發(fā)展前景。也使得該產(chǎn)業(yè)成為最活躍、進(jìn)展最快的領(lǐng)域，被公認(rèn)為21世紀(jì)最有前途的產(chǎn)業(yè)之一。我國(guó)生物醫(yī)藥行業(yè)的研究和開(kāi)發(fā)起步較晚，很多制度都不完善，尤其在資金治理結(jié)構(gòu)方面，存在著很大的隱患，造成市場(chǎng)風(fēng)險(xiǎn)大。倘若這些公司能對(duì)其所處行業(yè)的特征有充分的研究，能對(duì)經(jīng)營(yíng)風(fēng)險(xiǎn)予以加強(qiáng)，能對(duì)財(cái)務(wù)困境征兆予以足夠的重視并采取預(yù)警機(jī)制來(lái)加以控制，勢(shì)必將大大減少其陷入財(cái)務(wù)困境的可能性。因此,如何有效地運(yùn)用杠桿效應(yīng),并且如何規(guī)避財(cái)務(wù)風(fēng)險(xiǎn)和經(jīng)營(yíng)風(fēng)險(xiǎn),獲得杠桿效益,從而實(shí)現(xiàn)企業(yè)價(jià)值最大化是本論文的主要研究目標(biāo)。 本文總體上分為五個(gè)部分，第一部分為緒論，概括介紹了本文的選題背景和意義，，以及關(guān)于杠桿效應(yīng)理論的國(guó)內(nèi)外文獻(xiàn)綜述，并簡(jiǎn)述了本文的主要內(nèi)容、研究方法和創(chuàng)新點(diǎn)等問(wèn)題。第二部分杠桿效應(yīng)理論概述，就其產(chǎn)生根源和計(jì)量方法進(jìn)行分析。第三部分影響杠桿效應(yīng)因素分析，分別對(duì)影響經(jīng)營(yíng)杠桿、財(cái)務(wù)杠桿和總杠桿的因素進(jìn)行一一闡述。第四部分是本文的實(shí)證部分，選取生物制藥上市公司2009、2010、2011三年財(cái)務(wù)數(shù)據(jù)作為樣本，在分析杠桿均衡原理和財(cái)務(wù)定理的基礎(chǔ)上，篩選出利用杠桿均衡原理進(jìn)行風(fēng)險(xiǎn)管理的企業(yè)，對(duì)篩選的樣本進(jìn)行配對(duì)，選取入選及其配對(duì)公司的財(cái)務(wù)指標(biāo)為本實(shí)證的樣本數(shù)據(jù)。建立評(píng)價(jià)利用杠桿均衡原理進(jìn)行風(fēng)險(xiǎn)控制的財(cái)務(wù)評(píng)價(jià)模型，定量的判定上市公司是否杠桿均衡原理進(jìn)行風(fēng)險(xiǎn)控制。第五部分對(duì)前文的分析做出概括總結(jié)，主要是根據(jù)第五章的研究結(jié)果的小結(jié)；點(diǎn)明文章的局限性。
[Abstract]:As one of the seven strategic emerging industries, biopharmaceutical industry plays an important role in national economy and international strategic emerging industries. In recent years, a number of listed biopharmaceutical companies have taken advantage of the strong support of the capital market and have risen rapidly. Not only has the biopharmaceutical sector received much attention, but it has also been able to promote the development of the Chinese biopharmaceutical industry. Biopharmaceutical listed companies in the future have a broader development prospects. It also makes the industry one of the most active and developing fields, and is recognized as one of the most promising industries in the 21st century. The research and development of biopharmaceutical industry in our country started late, and many systems are not perfect, especially in the aspect of fund management structure, there are great hidden dangers, resulting in great market risks. If these companies can fully study the characteristics of their industries, they can strengthen the operational risks, pay sufficient attention to the signs of financial distress and adopt early warning mechanisms to control them. It is bound to greatly reduce its likelihood of financial distress. Therefore, how to use leverage effect effectively, how to avoid financial risk and management risk, how to obtain leverage benefit, and how to realize the maximization of enterprise value is the main research goal of this paper. This paper is divided into five parts as a whole. The first part is the introduction, which introduces the background and significance of the topic, and the domestic and foreign literature review on the leverage effect theory, and briefly describes the main content of this paper. Research methods and innovation points and so on. The second part summarizes the theory of leverage effect and analyzes its origin and measurement method. The third part analyzes the influencing factors of leverage, including the factors of management leverage, financial leverage and total leverage. The fourth part is the empirical part of this paper, which selects the financial data of biopharmaceutical listed companies in 2009 / 2010 / 2011 as a sample. On the basis of analyzing the principle of leverage equilibrium and financial theorem, the enterprises that use the principle of leverage equilibrium to carry out risk management are selected. The selected samples are matched and the financial indexes of the selected and matched companies are selected as the sample data of this empirical study. The financial evaluation model of risk control based on leverage equilibrium principle is established to quantitatively determine whether the listed company has leverage equilibrium principle to carry out risk control. The fifth part makes a summary of the previous analysis, mainly according to the conclusion of the fifth chapter, and points out the limitations of the article.
【學(xué)位授予單位】：沈陽(yáng)理工大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2013
【分類號(hào)】：F275;F426.72

【參考文獻(xiàn)】

中國(guó)期刊全文數(shù)據(jù)庫(kù) 前10條

1 楊玉波;資本結(jié)構(gòu)問(wèn)題中財(cái)務(wù)杠桿的作用[J];商業(yè)研究;2002年15期

2 彭孝松,楊義群;貝塔系數(shù)是風(fēng)險(xiǎn)的正確度量嗎[J];商業(yè)研究;2004年02期

3 李蕾;;中國(guó)上市公司財(cái)務(wù)杠桿總體水平實(shí)證研究[J];山東工商學(xué)院學(xué)報(bào);2009年04期

4 韋德洪,吳娜;上市公司資本結(jié)構(gòu)與業(yè)績(jī)相關(guān)性的實(shí)證研究[J];財(cái)會(huì)通訊(學(xué)術(shù)版);2005年08期

5 李偉翔;β系數(shù)與微觀經(jīng)濟(jì)杠桿之關(guān)系研究[J];財(cái)會(huì)通訊;2004年02期

6 羅福凱;營(yíng)業(yè)杠桿理論的改進(jìn)[J];財(cái)會(huì)通訊;2004年03期

7 陳華平;經(jīng)營(yíng)杠桿與經(jīng)營(yíng)杠桿度的論述[J];財(cái)會(huì)通訊;2004年10期

8 朱啟蓮,于慧源;淺談營(yíng)業(yè)杠桿系數(shù)及其應(yīng)用[J];財(cái)會(huì)月刊;1997年04期

9 馮太鳳;楊紅;林祥友;;對(duì)財(cái)務(wù)管理中杠桿效應(yīng)的新認(rèn)識(shí)[J];財(cái)會(huì)月刊;2007年02期

10 謝軍;;控股股東和財(cái)務(wù)杠桿的激勵(lì)功能[J];財(cái)經(jīng)理論與實(shí)踐;2006年04期

本文編號(hào)：2332697